What conventional chemotherapy does
Conventional cytotoxic chemotherapy works by interfering with cell division. Drugs like cisplatin, doxorubicin, paclitaxel, and 5-fluorouracil damage DNA, disrupt microtubules, or block nucleotide synthesis. Cancer cells divide faster than most normal cells, so the cumulative damage hits them harder. Normal tissues that also divide rapidly (bone marrow, gut lining, hair follicles, immune cells) take collateral damage. That is the source of the classic toxicity profile: cytopenias, mucositis, alopecia, immune suppression, neuropathy.
Standard chemotherapy is broadly indicated and accessible. It is FDA-approved across most cancer types. Lines of therapy escalate from first-line combinations to second, third, and fourth line as the disease progresses or becomes refractory.
What Targeted Osmotic Lysis does
Targeted Osmotic Lysis (TOL) is a two-component investigational platform. A cardiac glycoside drug (digoxin) inhibits the Na+/K+ ATPase pump. A pulsed electric field device activates voltage-gated sodium channels (NaV1.5, NaV1.7) that are over-expressed at 10 to 50 times normal density in many advanced solid tumors. The combination drives runaway sodium and water influx into the cancer cell, which ruptures. Normal cells lack the channel over-expression and recover when the drug clears.
TOL is investigational. It has not been approved by the FDA for cancer. Access is available through clinical trial enrollment, FDA Expanded Access (21 CFR 312 Subpart I), the federal Right to Try Act, COFEPRIS-authorized partner sites in Mexico, and the TGA Special Access Scheme in Australia.
How the two compare
| Dimension | Chemotherapy | Targeted Osmotic Lysis |
|---|---|---|
| Mechanism | Interferes with division | Selective osmotic rupture |
| Target | Any dividing cell | Voltage-gated sodium channel over-expressing cells |
| Off-target toxicity | Cytopenia, mucositis, alopecia, neuropathy | Limited; cardiac monitoring required given the glycoside |
| Approval status | FDA-approved across most cancers | Investigational, not FDA-approved |
| Access path | Standard prescription | Clinical trial, expanded access, Right to Try, international partner sites |
| Eligibility | Indication-specific; line of therapy escalation | Histology-agnostic where channel over-expression is documented |
When patients consider TOL
TOL is generally considered by stage 3 and stage 4 patients with refractory disease, after first- or second-line standard-of-care chemotherapy, immunotherapy, or targeted therapy has been exhausted. It is not a replacement for first-line standard of care.
The clinical team at the partner site reviews pathology, imaging, and treatment history before issuing a written eligibility assessment.
Submit your records for clinical eligibility review.
The clinical team reviews pathology, imaging, and treatment history. A written eligibility assessment returns in three to five business days.
Request eligibility review →